Overview Study of SOM0226 in Familial Amyloid Polyneuropathy Status: Completed Trial end date: 2015-11-01 Target enrollment: Participant gender: Summary Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis. Phase: Phase 1/Phase 2 Details Lead Sponsor: SOM Biotech SLCollaborator: Hospital Vall d'HebronTreatments: Tolcapone